REG - Oncimmune Hldngs PLC - PDMR Dealing

Oncimmune HoldingsAnnouncement

07/04/2020 11:45

RNS Number : 0688J
  
Oncimmune Holdings PLC
  
07 April 2020
  
 

Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
PDMR Dealing
 
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Matthew Hall, PDMR and Chief Financial Officer, has purchased 9,487 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for £0.527 per share on 7 April 2020.
 
Following this transaction, Matthew has a total interest in the Company of 9,487 Ordinary Shares, representing approximately 0.01 per cent of the Company's issued Ordinary Share capital.  
 
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 





 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 


Matthew Hall




2
 


Reason for the notification




a)
 


Position/status
 


Chief Financial Officer




b)
 


Initial notification /Amendment
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 


Oncimmune Holdings plc




b)
 


LEI


213800HCYIWT6YPI1I02 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of £0.01 each
 














Identification code


ISIN: GB00BYQ94H38














b)
 


Nature of the transaction
 


Purchase of shares




c)
 


Price(s) and volume(s)




























Price


Volume
















£0.527


9,487






























d)
 


Aggregated information


















- Aggregated volume


Same as above














- Price


















e)
 


Date of the transaction
 


7 April 2020




f)
 


Place of the transaction


London stock exchange, AIM



 
For further information:
Oncimmune Holdings plc
Andrew Stewart, General Counsel and Company Secretary
contact@oncimmune.com  
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHKKOBQKBKDKQK